IP Library Granted Patent US 8,808,764
Granted Patent B2
US 8,808,764 · App. 14/048,998 · Granted Aug 19, 2014

Methods and compositions for increasing growth hormones

Inventors: Amy L. Heaton (Salt Lake City, UT); Mitchell K. Friedlander (Salt Lake City, UT); Dennis Gay (Salt Lake City, UT)
Assignee: Quality IP Holdings, LLC
A61K36/538A61K31/401A23L1/00A61K31/198
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,808,764
App. No.
14/048,998
Granted
Aug 19, 2014
Kind
B2
Abstract

Embodiments of the invention generally relate to methods and supplements for improving the health of human beings.

Claims (37)

1. A nutritional supplement unit dosage form consisting essentially of:

about 1 mmol L-arginine;

about 1 mmol Oxo-proline;

about 2 mmol L-lysine;

about 1.5 μmol N-acetyl L-cysteine;

about 2 μmol L-glutamine; and

about 125 μg Schizonepta (aerial parts) powder.

2. The nutritional supplement unit dosage form of claim 1 , wherein the unit dosage form consists of:

0.86 mmol L-arginine;

1.32 mmol Oxo-proline;

2.05 mmol L-lysine;

1.53 μmol N-acetyl L-cysteine;

1.71 μmol L-glutamine; and

125 μg Schizonepta (aerial parts) powder.

3. The nutritional supplement unit dosage form of claim 2 , wherein the unit dosage form consists of 181.38 mg L-arginine HCl; 170.93 mg L-pyroglutamic acid; 374.83 mg L-lysine HCl; 0.25 mg N-acetyl L-cysteine USP; 0.25 mg L-glutamine; and 0.125 mg Schizonepta (aerial parts) powder.

4. The nutritional supplement unit dosage form of claim 1 , wherein the nutritional supplement unit dosage form is in capsule form.

5. A serving of the nutritional supplement unit dosage form of claim 2 , wherein the serving consists of:

3.44 mmol L-arginine;

5.30 mmol Oxo-proline;

8.21 mmol L-lysine;

6.13 μmol N-acetyl L-cysteine;

6.84 μmol L-glutamine; and

0.50 mg Schizonepta (aerial parts) powder.

6. The serving of claim 5 , wherein the serving consists of 725.50 mg L-arginine HCl; 683.70 mg L-pyroglutamic acid; 1499.30 mg L-lysine HCl; 1.00 mg N-acetyl L-cysteine USP; 1.00 mg L-glutamine; and 0.50 mg Schizonepta (aerial parts) powder.

7. A method for improving health in a human being in need thereof, the method comprising:

providing the nutritional supplement unit dosage form of claim 1 ; and

orally administering an effective amount of the nutritional supplement unit dosage form to the human being.

8. The method according to claim 7 , wherein the nutritional supplement unit dosage form is administered to the human being, in an amount effective to increase lean body mass; reduce obesity, adipose tissue mass, or anxiety; support weight loss; decrease appetite and atrophic processes in skeletal muscle, liver, kidney, spleen, skin, or bone; and/or improve energy, endurance, sleep, metabolism, heart rate, blood pressure, cardiovascular health, sympathetic nervous activity, thyroid response, fat metabolism, glucose utilization, mental/cognitive function, reaction time, bone density, hair health and appearance, nail health and appearance, skin health and appearance, and/or libido.

9. The method according to claim 7 , wherein the nutritional supplement unit dosage form is orally administered in a total amount of 2.9 grams.

10. The method according to claim 7 , wherein the nutritional supplement is administered from one to three times daily.

11. The method according to claim 7 , wherein the nutritional supplement is administered once a week.

12. The method according to claim 7 , wherein the nutritional supplement is administered on an empty stomach.

13. The method according to claim 7 , wherein the human being is at least 30 years old.

14. The method according to claim 7 , wherein the human being exhibits one or more symptoms of post-traumatic stress disorder selected from the group consisting of re-experiencing the original trauma(s) through flashbacks or nightmares, avoidance of stimuli associated with the trauma, increased arousal, difficulty falling or staying asleep, anger, and hypervigilance.

15. A method for improving health in a human being by increasing levels of human growth hormone in the human being, the method comprising:

orally administering an effective amount of a nutritional supplement to the human being, wherein the nutritional supplement consists essentially of 3.44 mmol L-arginine; 5.30 mmol Oxo-proline; 8.21 mmol L-lysine; 6.13 μmol N-acetyl L-cysteine; 6.84 μmol L-glutamine; and 0.50 mg Schizonepta (aerial parts) powder.

16. The method according to claim 15 , wherein the nutritional supplement consists of 725.50 mg L-arginine HCl; 683.70 mg L-pyroglutamic acid; 1499.30 mg L-lysine HCl; 1.00 mg N-acetyl L-cysteine USP; 1.00 mg L-glutamine; and 0.50 mg Schizonepta (aerial parts) powder.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Jan 5, 2023
From: CASPAR CAPITAL LP
To: QUALITY IP HOLDINGS LLC
Reel/Frame 062283/0073 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2022
From: CERBERUS BUSINESS FINANCE, LLC
To: CASPAR CAPITAL LP
Reel/Frame 061636/0625 →
ASSIGNMENT OF SECURITY INTEREST Recorded Dec 30, 2019
From: LS2, LLC
To: CERBERUS BUSINESS FINANCE, LLC
Reel/Frame 051447/0114 →
SECURITY INTEREST Recorded Aug 21, 2015
From: QUALITY IP HOLDINGS, LLC
To: LS2, LLC
Reel/Frame 036392/0053 →
ASSIGNMENT FOR SECURITY - PATENTS Recorded Dec 4, 2014
From: QUALITY IP HOLDINGS, LLC
To: CERBERUS BUSINESS FINANCE, LLC, AS COLLATERAL AGENT
Reel/Frame 034535/0294 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2014
From: HEATON, AMY L.; FRIEDLANDER, MITCHELL K.; GAY, DENNIS
To: QUALITY IP HOLDINGS, LLC
Reel/Frame 033307/0349 →
Continuity (2)
Continuation 13623110 · Sep 20, 2012
Related Publication 20140079832A1 · Mar 20, 2014